Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Chemical drugs | 1 |
Top 5 Target | Count |
---|---|
Akt-1 x Akt-2 x EGFR | 1 |
CHIKV E1 | 1 |
Target |
Mechanism CHIKV E1 antagonists |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AKT1 gene inhibitors [+2] |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Jun 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Licochalcone C ( Akt-1 x Akt-2 x EGFR ) | Mycobacterium Infections More | Preclinical |
PSSct1905 ( CHIKV E1 ) | Chikungunya Fever More | Preclinical |